Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

计划入组 100 人 · 首次发布于 2021 年 9 月 14 日

Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors

计划入组 157 人 · 首次发布于 2025 年 1 月 20 日

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma

计划入组 32 人 · 首次发布于 2023 年 6 月 8 日

PARP/MEK dual inhibitors (MD Anderson)

JAB-26766

Ribose

C₅H₁₀O₅

POLY MEDICURE LIMITED

India

Poly Pharmaceuticals Inc

United States

ANHUI POLY PHARM.CO.,LTD.

China

PARP Inhibitors Show Promise in Epithelial Ovarian and Breast Cancers with BRCA1/2 Mutations

Niraparib Maintenance Therapy Demonstrates Sustained Benefit in Recurrent Ovarian Cancer

PARP Inhibitors Show Promise in Ovarian Cancer Maintenance Therapy